Toxic aldehyde related diseases and treatment

Patent metadata

Field	Value
Publication number	US-9687481-B2
Application number	US-201414760039-A
Country	US
Kind code	B2
Filing date	Jan 23, 2014
Priority date	Jan 23, 2013
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

First claim

The invention claimed is:

1. A method of treating allergic conjunctivitis, comprising:
administering to a subject with allergic conjunctivitis a therapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein,
X is CH, Z is N; and Y is C with the —NH 2 attached;
p is 0, 1, 2, or 3;
each R B is independently a halogen, hydroxyl, carbamoyl, amino, or aryl;
R A is

and
Q a is C 1 -C 6 straight chain alkyl.

2. The method of claim 1 , wherein p is 1.

3. The method of claim 1 , wherein each Q a is methyl.

4. The method of claim 1 , wherein R B is a halogen.

5. The method of claim 4 , wherein the halogen is selected from chlorine and fluorine.

6. The method of claim 5 , wherein the halogen is chlorine.

7. The method of claim 1 , wherein the compound is present at a concentration from about 0.05 to about 10% w/v.

8. The method of claim 7 , wherein the compound is present at a concentration from about 0.1 to about 2% w/v.

9. The method of claim 7 , wherein the compound is present at a concentration from about 0.09 to about 0.5% w/v.

10. The method of claim 1 , wherein the compound present in an admixture with a cyclodextrin, or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 , wherein the cyclodextrin comprises a β-cyclodextrin or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein the β-cyclodextrin is selected from the group consisting of sulfobutylether-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, and 3-hydroxypropyl-β-cyclodextrin, and a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein the β-cyclodextrin is sulfobutylether-β-cyclodextrin or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein the salt of sulfobutylether-β-cyclodextrin is sulfobutylether-β-cyclodextrin sodium salt.

15. The method of claim 14 , wherein the sulfobutylether-β-cyclodextrin sodium salt is present at about 0.01 to about 30% w/v.

16. The method of claim 15 , wherein the sulfobutylether-β-cyclodextrin is present at about 2 to about 25% w/v.

17. The method of claim 16 , wherein the sulfobutylether-β-cyclodextrin is present at about 6 to about 20% w/v.

18. The method of claim 1 , wherein for the compound of formula (I):
R A is

R B is halogen; and
p is 1.

19. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20. The method of claim 1 , wherein the compound is administered topically to an eye of the subject with allergic conjunctivitis.

21. The method of claim 20 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

22. The method of claim 21 , wherein the compound is administered topically as an aqueous composition comprising the compound, and a cyclodextrin or a pharmaceutically acceptable salt thereof.

23. The method of claim 22 , wherein the cyclodextrin is a β-cyclodextrin or a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , wherein the β-cyclodextrin is sulfobutylether-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.

25. The method of claim 24 , wherein the β-cyclodextrin is hydroxypropyl-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.

26. The method of claim 25 , wherein the hydroxypropyl-β-cyclodextrin is 2-hydroxypropyl-β-cyclodextrin, 3-hydroxypropyl-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.

27. The method of claim 23 , wherein the β-cyclodextrin is sulfobutylether-β-cyclodextrin, or a pharmaceutically acceptable salt thereof.

28. The method of claim 27 , wherein the sulfobutylether-β-cyclodextrin is present at about 0.01% to about 30% w/v.

29. The method of claim 27 , wherein the sulfobutylether-β-cyclodextrin is present at about 5% to about 25% w/v.

30. The method of claim 28 , wherein the compound is present from 0.09 to 0.5% w/v.

31. The method of claim 28 , wherein the compound is present from 0.08 to 1% w/v.

32. The method of claim 1 , wherein the compound is present at a concentration from about 0.1 to about 5% w/v.

33. The method of claim 1 , wherein the compound is present at a concentration from about 0.05 to about 1.5% w/v.

34. The method of claim 28 , wherein the compound is present at a concentration from 0.04 to 10% w/v.

35. The method of claim 28 , wherein the compound is present at a concentration from 0.06 to 5% w/v.

Assignees

• Aldeyra Therapeutics Inc

Inventors

• Brady Todd
• Young Scott
• Kinney William A
• Mandell Kenneth J

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title